The US Food and Drug Administration ( FDA) has withdrawn emergency use of the anti-malaria drug hydroxychloroquine as a treatment for coronavirus.
The FDA said new evidence from clinical trials meant that the belief that the drug would produce an antiviral effect was no longer reasonable.
Withdrawing of hydroxychloroquine
Later, President Donald Trump defended the promotion of the use of hydroxychloroquine as a Covid-19 treatment.
For some serious cases the FDA granted the drug emergency use in March.
But on Monday, the agency said clinical studies had suggested that hydroxychloroquine was ineffective in treating the deadly virus and failed to prevent infection among those exposed to it.
Mr Trump said that he had previously taken the drug preventively without any side effects, in response to the FDA ‘s decision.
“I took it and felt good about taking it,” he said Monday to reporters, also adding: “I can’t complain about it, I’ve taken it for two weeks, and I’m here, we ‘re here.”
The chief, 74, said several people told him they had saved their lives.
Mr Trump announced in May that he was taking the drug. After testing positive for coronavirus by others in the White House.
His remarks on hydroxychloroquine became the subject of widespread online speculation and controversy within the scientific community. About the drug’s potential benefits and harmful effects-along with the associated drug, chloroquine.
Trials nationwide were temporarily halted after a report published in The Lancet reported that in some patients. The treatment had elevated deaths and cardiac attacks.
The findings prompted the World Health Organization (WHO) and others to halt safety trials.
Subsequently, however, The Lancet withdrew the analysis after it was found to have significant shortcomings. And the WHO also resumed its studies.
The US Food and Drug Administration ( FDA) has discontinued emergency usage of the anti-malaria medication hydroxychloroquine. As a cure for coronavirus.